COMMUNIQUÉS West-GlobeNewswire

Lifeward Names Mark Grant as New CEO
19/05/2025
Industry veteran brings 30 years of commercial leadership experience MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global [...]
Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy
19/05/2025
--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological (Blood) [...]
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
19/05/2025
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s [...]
MEDIROM Healthcare Technologies Inc. to Host Webcast on May 21, 2025 at 8:30 AM ET to Discuss 2024 Financial Results
19/05/2025
TOKYO, May 19, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”) today announced that it will host a webcast to [...]
Porch Light Health Partners with CHESS Health to Offer a Contingency Management Incentives Program to Boost SUD Treatment Outcomes
19/05/2025
DENVER, May 19, 2025 (GLOBE NEWSWIRE) -- Porch Light Health (PLH) has partnered with CHESS Health to use its innovative, automated Contingency Management Rewards Engine in the treatment of individuals with substance use [...]
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
19/05/2025
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead [...]
Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer
19/05/2025
Seasoned biopharma executive brings more than twenty years of business development, strategy, and operational expertise to Arbor’s leadership team CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies [...]
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
19/05/2025
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later [...]
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
19/05/2025
HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and [...]
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
19/05/2025
REYKJAVIK, ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider [...]
Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures
19/05/2025
May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to [...]
Trading in GN Store Nord shares by board members, executives and associated persons
19/05/2025
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
19/05/2025
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its [...]
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
19/05/2025
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it has commenced tender offers (the “ Offers ”) to purchase for cash for a [...]
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
19/05/2025
Proprietary formulation technology being applied to potentially enhance properties of nimacimab SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology [...]
Trading in GN Store Nord shares by board members, executives and associated persons
19/05/2025
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia
19/05/2025
The randomized, Phase 2, double-blind, placebo-controlled clinical trial will evaluate the potential of RJx-01 to maintain muscle integrity in older persons with severe acute exacerbation of COPD DIEPENBEEK, Belgium, [...]
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
19/05/2025
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle
19/05/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN BREVET CHINOIS PROTÉGEANT LE MASITINIB DANS LE TRAITEMENT DU COVID-19 JUSQU'EN 2041, AJOUTANT AINSI UNE INDICATION SUPPLÉMENTAIRE BÉNÉFICIANT D'UNE PROTECTION À LONG TERME DE LA [...]

Pages